Meta-analysis of vascular and neoplastic events associated with tamoxifen
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
OBJECTIVE: Tamoxifen reduces the risk of developing breast cancer but also affects the risks of certain vascular and neoplastic events. Our purpose was to estimate the effects of tamoxifen on potentially life-threatening vascular and neoplastic outcomes.
DESIGN: Random effects meta-analysis of published randomized controlled trials.
PATIENTS: Participants in all trials in which a treatment arm that included tamoxifen was compared to a similar control arm. Breast cancer risk reduction and treatment trials were included.
INTERVENTIONS: Tamoxifen at variable dose and duration.
MEASUREMENTS AND MAIN RESULTS: Thirty-two trials (52,929 patients) reported one or more outcomes of interest. Tamoxifen was associated with significantly increased risks of endometrial cancer (relative risk [RR] 2.70; 95% CI, 1.94 to 3.75), gastrointestinal cancers (RR 1.31; 95% CI, 1.01 to 1.69), strokes (RR 1.49; 95% CI, 1.16 to 1.90), and pulmonary emboli (RR 1.88; 95% CI, 1.77 to 3.01). Tamoxifen had no effect on secondary malignancies other than endometrial and gastrointestinal cancers (RR 0.96; 95% CI, 0.81 to 1.13). In contrast, tamoxifen significantly decreased myocardial infarction deaths (RR 0.62; 95% CI, 0.41 to 0.93) and was associated with a statistically insignificant decrease in myocardial infarction incidence (RR 0.90; 95% CI, 0.66 to 1.23). Postmenopausal women had greater risk increases for neoplastic outcomes.
CONCLUSIONS: This meta-analysis of randomized trials found tamoxifen use to be significantly associated with several neoplastic and vascular outcomes. Consideration of tamoxifen use requires balance of potential benefits and risks.
- Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–18. CrossRef
- Chlebowski RT. Reducing the risk of breast cancer. N Engl J Med. 1998;343:191–8. CrossRef
- Chlebowski RT, Col NF, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase reduction. J Clin Oncol. 2002;20:3328–43. CrossRef
- Anonymous. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451–67.
- Hasselblad V, McCrory DC. Meta-analytic tools for medical decision making: a practical guide. Med Decis Making. 1995;15:81–96. CrossRef
- Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Int Med. 1997;127:820–6.
- Berlin JA, Laird NM, Sacks HS, et al. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:141–51. CrossRef
- Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88. CrossRef
- Powles T, Eles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 1998;252:98–101.
- Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Lancet. 1998;352:93–7.
- Veronesi U, Maisonneuve P, Sacchini V, et al. Tamoxifen for breast cancer among hysterectomized women. Lancet. 2002;359:1122–4. CrossRef
- IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet. 2002;360:817–24. CrossRef
- Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529–42. CrossRef
- Fisher B, Constantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–37. CrossRef
- Constantino JP, Kuller LH, Ives DG, et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 1997;89:776–82. CrossRef
- Barner M, Bacchi M, Goldhirsch A, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase 3 multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol. 1994;12:2071–7.
- Ribeiro G, Swindell R. The Christie Hospital Adjuvant Tamoxifen Trial. J Natl Cancer Inst Monogr. 1992;11:121–5.
- Rutqvist LE, Johansson H. Signomkalo, et al. Adjuvant tamoxifen therapy for early stage breast cancer and secondary primary malignancies. J Natl Cancer Inst. 1995;87:645–51. CrossRef
- Ryden S, Ferno M, Moller T, et al. Long term effects of adjuvant tamoxifen and/or radiotherapy. Acta Oncol. 1992;31:271–4.
- Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst. 1991;83:1013–7. CrossRef
- Dalberg K, Johansson H, Johansson U. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Cancer. 1998;82:2204–11. CrossRef
- Rutqvist LE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst. 1993;85:1398–406. CrossRef
- Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J Clin Oncol. 1991;9:1740–8.
- Cummings FJ, Gray R, Tormey DC, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long term follow-up and causes of death. J Clin Oncol. 1993;11:29–35.
- Alwyn van Zyl J, Muller AG. Tumor excision plus continuous tamoxifen compared with modified radical mastectomy in patients over 70 years of age with operable breast cancer. J Surg Oncol. 1995;59:151–4. CrossRef
- Ingle JN, Everson LK, Wieland HS, et al. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. J Clin Oncol. 1988;6:1388–96.
- Ingle JN, Everson LK, Weiland HS, et al. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with nodepositive breast cancer. Cancer. 1989;63:1257–64. CrossRef
- Rivkin SE, Green S, Metch B, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group Study. J Clin Oncol. 1994;12:2078–85.
- Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994;86:1534–9. CrossRef
- Fisher B, Digham J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet. 1999;353:1993–2000. CrossRef
- Boccardo F, Rubagotti A, Amoroso D, et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) trial. Eur J Cancer. 1992;28:673–80. CrossRef
- Gundersen S, Hannisdal E, Soreide JA, et al. Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: a randomized study. Breast Cancer Res Treat. 1995;36:49–53. CrossRef
- Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. J Natl Cancer Inst Monogr. 1992;11:117–20.
- McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. BMJ. 1995;311:977–80.
- McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ. 1991;303:435–7. CrossRef
- Stewart HJ, Prescott RJ, Forrest PM. Scottish Adjuvant Tamoxifen Trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001;93:456–62. CrossRef
- Taylor SG, Kalish LA, Olson JE, et al. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, nodepositive breast cancer patients: three year results of an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1985;3:144–54.
- Tormey DC, Gray R, Taylor SG, et al. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer. J Natl Cancer Inst Monogr. 1986;1:75–80.
- Cocconi G, De Lisi V, Boni C, et al. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer. 1983;51:581–8. CrossRef
- Cocconi G, Di Blasio B, Bisagni G, et al. Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. Am J Clin Oncol. 1990;13:226–32. CrossRef
- Robertson JR, Ellis IO, Elston CW, et al. Mastectomy of tamoxifen as initial therapy for operable breast cancer in elderly patients: 5 year follow-up. Eur J Cancer. 1992;28A:908–10. CrossRef
- Andersson M, Kamby C, Jensen MB, et al. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B Trial. Eur J Cancer. 1999;35:1659–66. CrossRef
- The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrazol alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002;359:2131–9. CrossRef
- Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B23. J Clin Onc. 2001;19:931–42.
- Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000;92:903–11. CrossRef
- Rusthoven JJ, Quirt IC, Iscoe NA, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 1996;14:2083–90.
- Agarwala SS, Ferri W, Gooding W, et al. A phase 3 randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer. 1999;85:1979–84.
- Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992;327:516–23. CrossRef
- Kinsinger LS, Harris R, Woolf SH, et al. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:59–67.
- Newcomb P, Solomon C, White E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat. 1999;53:271–7. CrossRef
- Matsuyama Y, Tominaga T, Nomura Y, et al. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol. 2000;11:1337–43. CrossRef
- Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321–33. CrossRef
- Williams KJ, Wagner JD, Zhang L, et al. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol. 1997;17:403–8.
- Williams KJ, Honore EK, Adams MR. Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries nonhuman primates. Circulation. 1997;96:1970–75.
- Clarke SC, Schofield PM, Grace AA, et al. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation. 2001;103:1497–502.
- Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991;115:860–4.
- Cushman M, Tracy JP, Song RP, et al. Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol. 2001;21:255–61.
- Figtree GA, Webb CM, Collins P. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. J Pharmacol Exp Ther. 2000;295:519–23.
- Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med. 1992;152:317–20. CrossRef
- Reis SE, Constantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. J Natl Cancer Inst. 2001;93:16–21. CrossRef
- Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA. 2002;287:847–57. CrossRef
- Kuzick J. Update on new studies in Europe. Eur J Cancer. 2002;38:S20.
- Meta-analysis of vascular and neoplastic events associated with tamoxifen
Journal of General Internal Medicine
Volume 18, Issue 11 , pp 937-947
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- adverse events
- selective estrogen receptor
- Industry Sectors
- Author Affiliations
- 1. Section of Clinical Systems Modeling, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, 933 W-MUH, 200 Lothrop Street, 15213, Pittsburgh, PA
- 2. Harbor-UCLA Research and Education Institute, Torrance, Calif
- 3. Tufts-New England Medical Center, Boston, Mass
- 4. Dana Farber Cancer Center, Harvard Medical School, Boston, Mass
- 5. the Decision Systems Group and Division of General Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass